3-hexadecyloxy-2-benzothiophenecarboxylic acid | 1060773-08-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-hexadecyloxy-2-benzothiophenecarboxylic acid
• 英文别名: 3-Hexadecoxy-1-benzothiophene-2-carboxylic acid
• CAS: 1060773-08-1
• 化学式: C₂₅H₃₈O₃S
• 分子量: 418.641
• InChiKey: BVUMXQHSFXLOKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.5
• 重原子数：
  29
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Benzoxazinones and their use as ultraviolet light absorbers
  申请人：Clariant International Ltd.

  公开号：EP1972624A1

  公开（公告）日：2008-09-24

  The present invention relates to a new subclass of UV absorbers based on benzothiophene substituted benzoxazinones which can be used for stabilization of organic substrates, preferably in the protection of organic substrates against the damaging influence of light exposure.

  本发明涉及一种基于苯并噻吩取代苯并噁嗪酮的新型紫外线吸收剂亚类，可用于稳定有机基质，优选用于保护有机基质免受光照的有害影响。
• DISPERSANT FOR REDUCING VISCOSITY OF SOLIDS
  申请人：Eastman Kodak Company

  公开号：EP1971423A1

  公开（公告）日：2008-09-24
• Dispersant for Reducing Viscosity of Solids
  申请人：Pitt Alan R.

  公开号：US20080317960A1

  公开（公告）日：2008-12-25

  The invention provides a dispersant for an aqueous dispersion of negatively charged or chargeable solid particulates which comprises a compound having an anchoring moiety linked to a polymeric hydrophilic moiety, the anchoring moiety containing at least one basic group and having an overall basicity and the polymeric moiety having a lower affinity for the particulate surface than the anchoring moiety. The invention also provides a coating composition containing the dispersant, an inkjet recording element containing the dispersant and methods of coating or reducing viscosity using the dispersant.
• US8202926B2
  申请人：——

  公开号：US8202926B2

  公开（公告）日：2012-06-19
• [EN] COMBINATION OF A PTPase INHIBITOR AND AN ALPHA-GLUCOSIDASE INHIBITOR<br/>[FR] COMBINAISON D'UN INHIBITEUR DE PTPASE ET D'UN INHIBITEUR D'ALPHA-GLUCOSIDASE
  申请人：WYETH CORP

  公开号：WO2002098407A1

  公开（公告）日：2002-12-12

  This invention relates to pharmaceutical compositions and methods of treatment utilizing a PTPase (protein-tyrosine phosphatase) inhibitors and a glucosidase inhibitor, such as miglitol or acarbose, to lower the risk of cardiovascular disease and cardiovascular events in a mammal experiencing or subject to type II diabetes in mammals experiencing or subject to Syndrome X or type II diabetes (non-insulin-dependent diabetes mellitus), preferably in human type II diabetics.